切换至 "中华医学电子期刊资源库"

中华腔镜外科杂志(电子版) ›› 2023, Vol. 16 ›› Issue (01): 38 -43. doi: 10.3877/cma.j.issn.1674-6899.2023.01.010

论著

腹腔镜肝切除术治疗合并血小板减少肝细胞癌患者的疗效和安全性
赵晓飞1, 邸亮1, 张健2, 栗光明1, 曾道炳1,()   
  1. 1. 100069 北京,首都医科大学附属北京佑安医院普通外科中心;100069 北京,首都医科大学肝癌临床诊疗及研究中心
    2. 250101 济南,山东省济南市第三人民医院肝胆外科
  • 收稿日期:2023-01-10 出版日期:2023-02-28
  • 通信作者: 曾道炳
  • 基金资助:
    首都医科附属北京佑安医院2021年度院内中青年人才孵育项目(青年创新类)(YNKTQN2021017)

Efficacy and safety of laparoscopic liver resection for hepatocellular carcinoma with thrombocytopenia

Xiaofei Zhao1, Liang Di1, Jian Zhang2, Guangming Li1, Daobing Zeng1,()   

  1. 1. Department of General Surgery Center, Capital Medical University Affiliated Youan Hospital, Beijing 100069, China; Clinical Center for Liver Cancer, Capital Medical University, Beijing 100069, China
    2. Department of Hepatobiliary Surgery, The Third Hospital of Jinan, Shandong Province, Jinan 250101, China
  • Received:2023-01-10 Published:2023-02-28
  • Corresponding author: Daobing Zeng
目的

探讨腹腔镜肝切除(laparoscopic liver resection,LLR)对合并血小板减少肝细胞癌患者的有效性及安全性。

方法

回顾性分析2020年4月至2022年11月首都医科大学附属北京佑安医院因肝细胞癌行LLR的141例患者临床资料,根据血小板计数(PLT)是否<100×109/L分为PLT减少组和PLT正常组,比较两组患者术中出血量、肝门阻断比例、肝门阻断时间、手术时间、术中输血量、术中是否放置引流管、术后并发症、住院时间等数据,探讨PLT水平对LLR出血量的影响和手术的安全性。

结果

141例患者完成LLR,术中均未输注红细胞悬液,PLT减少组和PLT正常组的中位出血量分别为100 mL和50 mL,两组间差异无统计学意义(P=0.111),两组间肝门阻断比例、肝门阻断时间、手术时间和术中输血浆量均差异无统计学意义,PLT减少组放置引流管的比例明显高于PLT正常组(94.29%比78.50%,P=0.040);PLT减少组与PLT正常组术后并发症发生率差异无统计学意义(20.00%比10.28%,P=0.149);两组术后中位住院时间分别为7 d和6 d,差异无统计学意义(P=0.062)。

结论

通过仔细解剖、适当地肝门阻断和低中心静脉压技术,对合并血小板减少的肝细胞癌患者实施LLR是安全、可行的,经验丰富的腹腔镜肝脏外科医师还可以做到无输血LLR。

Objective

To investigate the effect of laparoscopic liver resection(LLR) on intraoperative bleeding in hepatocellular carcinoma (HCC) patients with thrombocytopenia.

Methods

The clinical data of 141 patients who underwent LLR for HCC in Department of General Surgery Center, Capital Medical University Affiliated Youan Hospital from Apr.2020 to Nov. 2022 were analyzed retrospectively. According to the level of PLT, they were divided into PLT reduced group and PLT normal group. The blood loss during operation, the proportion of hepatic portal occlusion, the time of hepatic portal occlusion, the time of operation, the amount of blood transfusion during operation, whether drainage tubes were placed during operation, the complications after operation, and the length of hospital stay were compared between the two groups, To investigate the effect of PLT level on the amount of bleeding and the safety of LLR.

Results

141 patients completed LLR without intraoperative infusion of red blood cells. The median bleeding volume of PLT reduced group and PLT normal group was 100 mL and 50 mL respectively. There was no statistical difference between the two groups (P=0.111). There was no statistical difference between the two groups in the time of hepatic portal occlusion, the operation time, the proportion of hepatic portal occlusion, and the amount of intraoperative plasma transfusion. The proportion of drainage tubes of PLT reduced group was significantly higher than that of PLT normal group (94.29% vs 78.50%, P=0.040) There was no statistical difference in the incidence of postoperative complications between the PLT reduced group and the PLT normal group (20.00% vs 10.28%, P=0.149). The hospital stay after surgery was 7 days and 6 days respectively and there was no difference between the two groups (P=0.062).

Conclusions

LLR is safe and feasible for HCC patients with thrombocytopenia through careful anatomy, appropriate hepatic portal occlusion and low central venous pressure technology, and LLR without blood transfusion can also be performed by experienced hepatobiliary surgeon.

表1 两组合并血小板减少肝细胞癌患者基线资料比较
项目 血小板计数减少组(35例) 血小板计数正常组(107例) 统计值 P
年龄(岁,±s) 58.37±8.58 55.32±10.88 1.500 0.139
性别[例(%),男/女] 29(82.86)/6(17.14) 87(81.31)/20(18.69) 0.420 0.834
病因[例(%)]     6.900 0.431
HBV 26(74.29) 81(75.70)    
HCV 3(8.57) 6(5.61)    
酒精性肝病 1(2.86) 9(8.41)    
脂肪肝 1(2.86) 3(2.80)    
不明原因 3(8.57) 2(1.87)    
无肝病 1(2.86) 1(0.93)    
HBV+HCV 0(0.00) 1(0.93)    
HBV+酒精性 0(0.00) 3(2.80)    
Child-Pugh分级[例(%),A/B] 32(91.43)/3 (8.57) 103(96.26)/4(3.74) 1.310 0.364
WBC(×109/L) 3.23(2.90~4.34) 5.38(4.58~6.65) -6.691 <0.001
HGB(g/L) 139.00(133.00~148.00) 145.00(133.00~158.00) -1.584 0.113
PLT(×109/L) 71.00(58.00~86.00) 172.00(143.00~207.00) -8.864 <0.001
INR 1.14(1.11~1.23) 1.04(0.99~1.09) -6.145 <0.001
Tbil(μmol/L) 23.70(15.80~34.70) 18.10(13.00~23.10) -3.207 0.001
ALB(g/L) 39.50(37.60~42.40) 41.60(39.10~44.00) -2.301 0.021
AFP(ng/mL) 5.65(2.33~42.50) 8.03(3.37~184.00) -1.910 0.056
腹部手术史[例(%),有/无] 8(22.86)/27(77.14) 16(14.95)/91(85.05) 1.170 0.303
门静脉高压症[例(%),有/无] 33(94.29)/2(5.71) 64(59.81)/43(41.19) 31.02 <0.001
肝癌分期[例(%)]        
CNLC(Ⅰ/Ⅱ/Ⅲ/Ⅳ) 30(85.71)/4(11.43)/0(0.00)/1(2.86) 87(81.31)/12(11.21)/6(5.61)/2(1.87) 2.140 0.542
BCLC(0/A/B) 14(40.00)/20(57.14)/1(2.86) 29(27.10)/66(61.68)/12(11.21) 3.550 0.169
肿瘤位置[例(%)]     2.726 0.909
1(2.86) 2(1.87)    
3(8.57) 6(5.61)    
4(11.43) 12(11.21)    
3(8.57) 11(10.28)    
8(22.86) 29(27.10)    
6(17.14) 22(20.56)    
7(20.00) 12(11.21)    
3(8.57) 13(12.15)    
表2 两组合并血小板减少肝细胞癌患者术中资料比较
表3 两组合并血小板减少肝细胞癌患者术后资料比较
1
Abu Hilal M, Aldrighetti L, Dagher I,et al. The southampton consensus guidelines for laparoscopic liver surgery: from indication to implementation[J]. Annals of surgery2018268(1):11-18.
2
Chao YJ, Wang CJ, Shan YS. Technical notes: a self-designed, simple, secure, and safe six-loop intracorporeal pringle's maneuver for laparoscopic liver resection[J]. Surgical endoscopy201226(9):2681-2686.
3
Heaney JP, Stanton WK, Halbert DS,et al. An improved technic for vascular isolation of the liver: experimental study and case reports[J]. Annals of surgery, 1966163(2):237-241.
4
Hendi M, Lv J, Cai XJ. Current status of laparoscopic hepatectomy for the treatment of hepatocellular carcinoma: a systematic literature review[J]. Medicine2021100(50):27826.
5
Liu TS, Shen QH, Zhou XY,et al. Application of controlled low central venous pressure during hepatectomy: a systematic review and meta-analysis[J]. Journal of clinical anesthesia202175:110467.
6
O′Leary JG, Greenberg CS, Patton HM, et al.Aga clinical practice update: coagulation in cirrhosis[J]. Gastroenterology2019157(1):34-43.
7
Latorre R, Vaquero J, Rincon D, et al. Determinants of platelet count are different in patients with compensated and decompensated cirrhosis[J]. Liver Int201636(2):232-239.
8
曾道炳,邸亮,高大明,等. 完全腹腔镜下肝尾状叶原发性肝癌切除术一例[J]. 中华肝胆外科杂志2016, 22(1): 32,61.
9
曾道炳,邸亮,丁兢,等. 腹腔镜解剖性肝左外叶切除的技术改进[J]. 肝胆胰外科杂志2018, 30(4):324-326.
10
刘荣,赵国栋. 肝左外叶切除"金标准"术式:腹腔镜肝左外叶切除术[J/CD]. 中华腔镜外科杂志(电子版), 20103(6):474-478.
11
余海波,彭亚南,董亚东,等. 加速康复外科在腹腔镜精准肝切除中的应用价值[J]. 中华普通外科杂志2018, 33(5): 401-404.
12
中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗指南(2022年版)[J]. 中华肝脏病杂志2022, 30(4): 367-388.
13
谢国伟,李嘉鑫,吴泓. 吲哚氰绿荧光显像导航技术在复发性肝癌腹腔镜再次肝切除中的应用[J/CD]. 中华肝脏外科手术学电子杂志2020, 9(2): 153 -157.
14
赵国栋,马奔,刘荣. 肝脏流域学说下的控血新理念:适时分合肝脏控血技术[J]. 中华医学杂志2021, 101(40): 3261-3265.
15
刘荣,赵国栋. 肝脏解剖:从尸体静态解剖学下的树干理论到临床潜能形态学下的流域学说[J/CD]. 中华腔镜外科杂志(电子版)201811(5):257-260.
16
Tripodi A, Chantarangkul V, Primignani M, et al. Thrombin generation in plasma from patients with cirrhosis supplemented with normal plasma: considerations on the efficacy of treatment with fresh-frozen plasma[J]. Internal and emergency medicine20127(2):139-144.
17
Pang Q, Zhang JY, Liu SS, et al. Adverse effects of platelets on post-hepatectomy outcomes in patients with hepatocellular carcinoma[J]. Journal of hepatology, 201664(2):518-519.
18
何国林,洪合,程远,等. 快速康复外科理念在腹腔镜肝切除术中的应用[J]. 中华普通外科杂志2018, 33(8): 635-637.
[1] 汪瀚韬, 张炜彬, 范培丽, 董怡, 陆清, 朱正, 王文平. 肝神经内分泌肿瘤和肝细胞癌超声影像学特征对比[J]. 中华医学超声杂志(电子版), 2023, 20(01): 70-77.
[2] 陈凯玲, 张炜彬, 毛枫, 韩红, 李超伦, 董怡, 王文平. 肝细胞腺瘤与肝细胞癌超声造影特征对比[J]. 中华医学超声杂志(电子版), 2022, 19(11): 1218-1224.
[3] 邹旻红, 林伟珍, 黄庆, 蒋叶, 张娈景, 郑荣琴. 肝细胞腺瘤的临床及超声特点分析[J]. 中华医学超声杂志(电子版), 2022, 19(11): 1225-1231.
[4] 尹宏祥, 段家康, 江博文, 谈燚. 全身免疫炎症指数联合预后营养指数对接受根治性切除术的肝细胞癌的预后价值研究[J]. 中华普通外科学文献(电子版), 2023, 17(02): 93-98.
[5] 马铭秀, 徐锋, 谢铠岭, 郭亚明, 卢潼辉, 戴朝六. 术前碱性磷酸酶-前白蛋白比值对肝细胞癌切除术预后的评估价值[J]. 中华普通外科学文献(电子版), 2023, 17(02): 99-103.
[6] 郑希彦, 周正, 何方平, 林志群, 杜飞, 谢琴, 王少平, 史宪杰. 代谢综合征与乙型肝炎病毒相关性肝细胞癌预后的危险因素分析[J]. 中华普通外科学文献(电子版), 2023, 17(02): 104-109.
[7] 曹亚娟, 黎兵华, 余德才. 转化治疗联合Laennec入路机器人右半肝切除治疗进展期肝癌[J]. 中华腔镜外科杂志(电子版), 2023, 16(02): 116-119.
[8] 刘虎, 张搏伦, 杨豪, 乐羿, 刁广浩, 崔昭扬, 赵向宁, 安亮, 李海珠, 蔡建强, 张绍庚. 弯曲形水冷微波消融针在腹腔镜下膈顶部肝细胞癌消融中的应用[J]. 中华腔镜外科杂志(电子版), 2023, 16(01): 44-48.
[9] 周鹏宇, 涂志坚, 李传富, 雷晓华, 陈国栋. 机器人解剖性右肝后叶切除术[J]. 中华腔镜外科杂志(电子版), 2023, 16(01): 56-59.
[10] 黄洁. 腹腔镜肝脏手术中一些值得深入思考的问题[J]. 中华肝脏外科手术学电子杂志, 2023, 12(03): 267-271.
[11] 刘中百, 任勇军. 肝细胞癌的介入治疗现状及进展[J]. 中华消化病与影像杂志(电子版), 2023, 13(02): 111-115.
[12] 童译庆, 张建明, 贺星星, 傅一牧, 赵刚, 封启明. 基于贝叶斯网络模型在脓毒症患者血小板减少症发生因素中的分析[J]. 中华临床医师杂志(电子版), 2022, 16(11): 1120-1125.
[13] 梁伟, 王晓彬, 洪笑阳, 蔡明岳, 梁礼聪, 陈烨, 黄培凯, 刘铭宇, 林立腾, 朱康顺. 原位肝癌小鼠微波消融术后复发模型的构建[J]. 中华介入放射学电子杂志, 2023, 11(02): 133-139.
[14] 张玉冰, 陈彦晖, 沈新颖. 局部消融术联合免疫检查点抑制剂治疗肝癌的研究进展[J]. 中华介入放射学电子杂志, 2023, 11(01): 68-73.
[15] 韦慧萍, 郭瑛明, 刘桂荣, 巫宗由, 翁秋青. 超氧化物歧化酶检测在乙型肝炎病毒相关性肝病中的应用价值[J]. 中华临床实验室管理电子杂志, 2023, 11(01): 21-26.
阅读次数
全文


摘要